solute carrier family 33 member 1Genealiases: ACATN · AT-1 · AT1 · CCHLND · HPBDS · SPG42
Q-omics provides the consensus-scored SLC33A1 profile across patient tissues and cancer cell-line models. SLC33A1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC33A1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SLC33A1 RNA expression shows 20,432 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where SLC33A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC33A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC33A1 survival associations across molecular data types. SLC33A1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC33A1 RNA expression–survival associations across cancer types. High SLC33A1 expression shows unfavorable associations in LGG, LIHC and SKCM, but favorable associations in KIRC, COAD and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC33A1 RNA expression.
This table summarizes SLC33A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC33A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC33A1 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, BLCA and LUAD. The HNSC box plot shows higher SLC33A1 RNA expression in tumor versus normal tissue (log2 FC = +0.956, t-test p < 0.001).
This table shows molecular features associated with SLC33A1 in patient tissues and cancer cell lines. In patient samples, SLC33A1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC33A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
